Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
2021 · Cell · 537 citations
https://doi.org/10.1016/j.cell.2021.11.017
K
Kevin S. Kapner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
317
Papers
1.4K
Citations
13
h-index
15
i10-index
Kevin S. Kapner is an academic researcher from Dana-Farber Cancer Institute. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics & Colorectal Cancer Treatments and Studies. The author has an h-index of 13, co-authored 270 publications.
ORCID: 0000-0002-2306-2373Papers by this author
worksMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
2024 · Cancer Discovery · 196 citations
https://doi.org/10.1158/2159-8290.cd-24-0177
Sotorasib Is a Pan- <i>RAS</i> G12C Inhibitor Capable of Driving Clinical Response in <i>NRAS</i> G12C Cancers
2024 · Cancer Discovery · 38 citations
https://doi.org/10.1158/2159-8290.cd-23-1138
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
2024 · Nature Communications · 14 citations
https://doi.org/10.1038/s41467-024-51271-3
Integrative genomic identification of therapeutic targets for pancreatic cancer
2025 · Cell Reports · 3 citations
https://doi.org/10.1016/j.celrep.2025.116191
Supplementary Figure 6 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25603651.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat